Grant List
Represents Grant table in the DB
GET /v1/grants?sort=-funder
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-funder", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=-funder", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=2&sort=-funder", "prev": null }, "data": [ { "type": "Grant", "id": "5811", "attributes": { "award_id": "1R41AI157347-01A1", "title": "COVID-19: High Efficiency SARS-CoV-2 Virus Aerosol Sampling and Sensing", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 19961, "first_name": "Erik J.", "last_name": "Stemmy", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-07-06", "end_date": "2023-06-30", "award_amount": 262802, "principal_investigator": { "id": 19962, "first_name": "Patricia Bea", "last_name": "Keady", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1123, "ror": "", "name": "AEROSOL DEVICES, INC.", "address": "", "city": "", "state": "CO", "zip": "", "country": "United States", "approved": true }, "abstract": "As the current COVID-19 pandemic has demonstrated, aerosolized pathogens such as SARS-CoV-2 can spread explosively if not quickly detected. Early detection of these airborne pathogens can help control out- breaks, particularly within vulnerable populations in densely populated spaces including assisted living facili- ties, places of worship, military installations, hospitals, and prisons. To date, most studies of aerosolized SARS-CoV-2 use filter collection followed by laboratory analysis of viral RNA. While this gives a general indica- tion of viral RNA levels in an environment, filters collect both infectious and non-infectious viruses and damage them through mechanical stress and desiccation, making it difficult to determine the infective fraction of the col- lected viruses. Further, current filter analysis methods require time-consuming nucleic acid extraction and am- plification techniques not suitable to rapid, point-of-care monitoring. Therefore, there is an urgent need for in- struments that can detect intact viruses at the point-of-care. We propose to develop a sensitive, direct reading, bioaerosol detection platform that can quantify specific air- borne pathogens at the point of collection. Furthermore, if a positive result is identified, the sample can be taken to a central laboratory for additional molecular analysis and infectivity testing. This device will integrate the bioaerosol collection technology developed at Aerosol Devices Inc. (ADev) with virus detection technology from Colorado State University (CSU). Using gentle condensation-growth capture that mimics the human lung, the ADev sampler will be the front-end of the platform, concentrating intact, viable virus particles into a small liquid volume. With >90% collection efficiency for particle sizes <10 nm up to 10 µm, ADev samplers uniformly collect all inhalable SARS-CoV-2 particles whether originating from cough droplets (>5 µm), smaller particles exhaled during breathing or talking (<5 µm), or shed as individual virus particles (~120 nm). CSU Professors Henry, Dandy, and Geiss are developing innovative, inexpensive electrochemical biosensors to rapidly detect intact viruses in liquid samples. By synergizing these robust sensors with the ADev aerosol sampler, we will produce a system that can detect and quantify ultra-low concentrations of viral pathogens in near real-time. In this phase I STTR project, we will adapt our commercial aerosol-into-liquid collector to incorporate CSU’s biosensors. Specific aims for the ADev sampler include extending sampling time to 24 h to enhance limits of detection, increasing volumetric sampling rate to improve temporal resolution, selecting materials compatible with VHP decontamination and optimizing the system to reduce size, weight, power consumption and cost. Specific aims for the biosensor include modifying electrodes to detect SARS-CoV-2 particles with high sensitiv- ity and selectivity, adapting our current electrode configuration to work with the ADev sampling vial, and testing the system with infectious SARS-CoV-2 in our BSL-3 laboratory. Our immediate focus is SARS-CoV-2, but this technology can be adapted in Phase II to detect any airborne pathogen (e.g., Influenza, B. anthracis, etc.).", "keywords": [ "2019-nCoV", "Abate", "Aerosols", "Air", "Antibodies", "Assisted Living Facilities", "Bacillus anthracis", "Bacteria", "Binding", "Biosensor", "Bluetooth", "Bordetella pertussis", "Breathing", "Buffers", "COVID-19", "COVID-19 detection", "COVID-19 pandemic", "Collaborations", "Collection", "Colorado", "Consumption", "Coughing", "Decontamination", "Desiccation", "Detection", "Devices", "Disease", "Disease Outbreaks", "Early Diagnosis", "Electrodes", "Ensure", "Environment", "Exhalation", "Exposure to", "Future", "General Population", "Goals", "Growth", "Health Personnel", "Health care facility", "Hospitals", "Hour", "Human", "Individual", "Influenza", "Influenza B Virus", "Intervention", "Label", "Laboratories", "Liquid substance", "Long-Term Care", "Lung", "Measles", "Mechanical Stress", "Methods", "Military Personnel", "Molecular Analysis", "Monitor", "Nucleic Acids", "Nursing Homes", "Outcome", "Particle Size", "Patients", "Phase", "Physical condensation", "Play", "Prisons", "RNA", "Reading", "Recovery", "Reporting", "Resolution", "Reverse Transcriptase Polymerase Chain Reaction", "SARS-CoV-2 antibody", "SARS-CoV-2 infection", "SARS-CoV-2 spike protein", "SARS-CoV-2 transmission", "Sampling", "Small Business Technology Transfer Research", "Social Impacts", "Spectrum Analysis", "Sterility", "Structure", "Surface", "System", "Techniques", "Technology", "Testing", "Time", "Transportation", "Tube", "Universities", "Vial device", "Virion", "Virus", "Vulnerable Populations", "Weight", "Work", "aerosolized", "base", "cost", "detection limit", "detection method", "detection platform", "economic impact", "electric impedance", "improved", "innovation", "instrument", "operation", "pandemic disease", "particle", "pathogen", "pathogenic virus", "point of care", "prevent", "professor", "prototype", "respiratory", "respiratory pathogen", "sensor", "temporal measurement", "tool", "transmission process", "viral RNA", "viral detection", "virology" ], "approved": true } }, { "type": "Grant", "id": "15995", "attributes": { "award_id": "1IK2HX003695-01A2", "title": "Improving Specialty Care Through Virtual Care Models", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2026-01-01", "end_date": "2030-12-31", "award_amount": null, "principal_investigator": { "id": 44448, "first_name": "Rebecca", "last_name": "Tisdale", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 3442, "ror": "", "name": "VETERANS ADMIN PALO ALTO HEALTH CARE SYS", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "1 Background: Specialty care deserts—the absence of specialists in geographic regions—have led to an access 2 crisis for the VA. In addition to increasing wait times and causing delays in care, these access needs drive many 3 Veterans to seek care outside VA, resulting in fragmented care, increased risks for hospitalization and hospital 4 readmission, and higher costs. In response, VA has launched the Clinical Resource Hub (CRH) program, which 5 seeks to deliver virtual care from “hub” to “spoke” sites in VA. VISN 21 has begun implementing this model in 6 cardiology at several spoke sites, but little is known about how care utilization and quality within the program. 7 Significance/Impact: This work seeks to better understand the effects of a virtual model of specialty care, in 8 this case cardiology care, on Veterans’ care access and quality. In addition, it aligns closely with several VA and 9 HSR&D priorities, chiefly access to care, virtual care/telehealth, and advancing the goals of the MISSION Act. 10 Innovation: The CRH program and the virtual care model at its core have yet to be studied in depth, and there 11 is no research in progress regarding specialty CRH despite strong interest at the national VA level in 12 understanding how specialty CRH is used and associated outcomes. Given that virtual cardiology care was very 13 limited prior to the COVID-19 pandemic, cardiology CRH is particularly novel. Hence, this project would add to 14 the limited body of research examining virtual cardiology care in the VA. In addition, the proposed work seeks to 15 evaluate this virtual care model at a time of unprecedented choice for Veterans between in-person and virtual 16 care, and limited data on how best to integrate these modalities. 17 Specific Aims: The proposed CDA will offer mentorship and training for me to pursue the following aims: 18 Aim 1. Evaluate quality of cardiology care associated with CRH implementation with administrative data. 19 I will use adjusted difference-in-difference event studies to compare cardiology quality metric achievement for 20 patients who received cardiology care via CRH versus those who received conventional VA-based cardiology care. 21 Aim 2. Assess Veteran perceptions of quality of cardiology care delivered via CRH. 22 I will interview Veterans participating in the CRH program and their caregivers regarding their experiences and 23 perceptions of quality of CRH cardiology care and elicit suggestions for key metrics to focus on for improvement. 24 Aim 3. Construct intervention to track and improve access to high-quality, equitable care through CRH. 25 Building on finding from Aims 1 and 2, I will interview clinicians and employ a facilitated deliberative process with 26 an expert advisory group to construct and pilot an intervention to improve quality. 27 Methodology: In Aim 1, I will use a difference-in-difference event study design to assess the impact of the program 28 on a battery of validated and/or guideline-based quality of cardiology care metrics. In Aim 2, guided by the Fortney 29 model of care access and quality, I will conduct semi-structured interviews of Veterans and caregivers receiving 30 care through the VISN 21 CRH program to understand their experiences with the CRH program and what outcomes 31 they recommend to include in a quality improvement intervention. In Aim 3, I will interview clinicians (Aim 3.1) and 32 conduct a facilitated deliberation process (Aim 3.2) to inform the construction of an intervention (proactive panel 33 management using a clinical dashboard tool) to track and improve quality of care and pilot the intervention. 34 Next Steps/Implementation: To continue moving this research into practice to improve health outcomes for 35 Veterans, I will extend the analysis of cardiology quality of care to compare cardiology care in the community to 36 CRH care. In addition, I will assess the effect of the intervention constructed in Aim 3 on patient outcomes and 37 clinician satisfaction via a hybrid implementation-effectiveness trial. I will continue to work with operational partners 38 to ensure cardiology CRH is improving access to high-quality cardiology care for Veterans. This project supports 39 my goal of becoming an independent VA health services researcher and leader in optimizing cardiovascular 40 disease care access, value, and equity for Veterans through virtual care innovations and implementation.", "keywords": [ "Achievement", "Address", "Area", "COVID-19 pandemic", "California", "Cardiology", "Cardiovascular Diseases", "Cardiovascular system", "Caregivers", "Caring", "Characteristics", "Cladribine", "Clinical", "Clinical Services", "Communities", "Community Health Care", "Dangerousness", "Data", "Disease", "Ensure", "Equity", "Evaluation", "Event", "Geographic Locations", "Goals", "Guidelines", "Health", "Health Services", "Health Services Accessibility", "Heart failure", "Homogeneously Staining Region", "Hospitalization", "Hospitals", "Improve Access", "Intervention", "Interview", "Medical", "Mentors", "Mentorship", "Methodology", "Methods", "Modality", "Modeling", "Morbidity - disease rate", "Nevada", "Outcome", "Pacific Islands", "Patient-Focused Outcomes", "Patients", "Perception", "Persons", "Physicians", "Policies", "Positioning Attribute", "Process", "Qualitative Methods", "Quality of Care", "Recommendation", "Research", "Research Design", "Research Personnel", "Resources", "Risk", "Rural Health", "Safety", "Site", "Specialist", "Structure", "Suggestion", "Telemedicine", "Telephone", "Testing", "Time", "Training", "Training Activity", "Veterans", "Visit", "Wait Time", "Work", "adverse outcome", "care fragmentation", "care seeking", "care utilization", "clinical implementation", "connected care", "cost", "dashboard", "design", "effectiveness/implementation trial", "experience", "follow-up", "health economics", "hospital readmission", "hospitalization rates", "implementation efforts", "implementation science", "improved", "innovation", "insight", "interest", "intervention effect", "medical specialties", "mortality", "novel", "operation", "patient subsets", "pilot test", "preference", "programs", "rapid growth", "research to practice", "response", "rural counties", "satisfaction", "sociodemographics", "southern nevada", "telehealth", "therapy design", "tool", "virtual", "virtual delivery", "virtual health care", "virtual model" ], "approved": true } }, { "type": "Grant", "id": "10487", "attributes": { "award_id": "3R00AT009466-04S1", "title": "Affective Sensory Pathways of Light Stroking and Deep Pressure Touch", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Complementary and Integrative Health (NCCIH)" ], "program_reference_codes": [], "program_officials": [ { "id": 26496, "first_name": "Alexander H.", "last_name": "Tuttle", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-06-01", "end_date": "2023-11-30", "award_amount": 219375, "principal_investigator": { "id": 26497, "first_name": "Laura K", "last_name": "Case", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 760, "ror": "https://ror.org/0168r3w48", "name": "University of California, San Diego", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Administrative Supplement Proposal: Abstract R00 AT009466: Affective Sensory Pathways of Light Stroking and Deep Pressure Touch Dr. Case is as an Assistant Professor in the Department of Anesthesiology at the University of California San Diego (UC San Diego). After overcoming covid-related delays, her R00 study on mechanisms of affective touch is running smoothly and on track with her current SARP. The proposed administrative supplement is requested to add two highly innovative aims to increase the impact of the originally proposed study in establishing novel mechanisms of action for sensory-based complementary approaches such as massage therapy. The existing R00 study seeks to identify factors underlying blunted affective touch perception in individuals with chronic pain, and to compare the pain-relieving mechanisms and effects of light gentle stroking and deep pressure between patients with Fibromyalgia (FM) and healthy controls. The current administrative proposal adds two aims: 5) Determine the local effect of subcutaneous OT on experimental pain and 6) Determine the local effect of subcutaneous OT on touch pleasantness. Recent research in rodents demonstrates that oxytocin strongly modulates C-fibers in the spinal cord and at the terminal axon. In humans, systemic oxytocin modulates affective touch perception, and skin injection reduces postsurgical pain. However, peripheral effects of oxytocin on affective touch perception have never been tested in humans. Study results are expected to significantly impact fundamental understanding of the mechanisms of peripheral pathways for touch pleasantness and pain reduction. We expect this project to lead to a competitive R01 submission to test whether local effects of oxytocin differ in patients with chronic pain, who exhibit C-nociceptor sensitization and reduced touch pleasantness. This contribution will inform subsequent research on mechanisms of manual touch therapies and provide a new direction to test differences in individuals with chronic pain.", "keywords": [ "Acute Pain", "Administrative Supplement", "Adult", "Affective", "Analgesics", "Anesthesiology", "Anxiety", "Area", "Attention", "Blood", "C Fiber", "California", "Clinical Treatment", "Cross-Over Studies", "Dorsal", "Dose", "Double-Blind Method", "Emotional", "Enrollment", "Enzyme-Linked Immunosorbent Assay", "Esthesia", "Exhibits", "Forearm", "Fright", "Heart Rate", "Human", "Immunoassay", "Individual", "Injections", "Institutional Review Boards", "Insula of Reil", "Isotonic Exercise", "Lead", "Light", "Manipulative Therapies", "Manuals", "Massage", "Measures", "Mechanics", "Mechanoreceptors", "Mediating", "Mediator of activation protein", "Moods", "Mus", "Nerve", "Neurons", "Neuropeptides", "Nociception", "Nociceptors", "Opioid Antagonist", "Oxytocin", "Oxytocin Receptor", "Pain", "Pain Threshold", "Pain intensity", "Participant", "Pathway interactions", "Perception", "Peripheral", "Placebos", "Postoperative Pain", "Predictive Factor", "Presynaptic Terminals", "Process", "Research", "Rodent", "Role", "Running", "Saline", "Sensory", "Skin", "Spinal Cord", "Spinal Ganglia", "Stimulus", "Stress", "Tactile", "Testing", "Therapeutic tactile stimulation", "Touch sensation", "Transcranial magnetic stimulation", "Universities", "autism spectrum disorder", "base", "chronic pain", "chronic pain management", "chronic pain patient", "coronavirus disease", "experience", "fibromyalgia patients", "injured", "innovation", "light effects", "nerve injury", "novel", "pain behavior", "pain model", "pain perception", "pain reduction", "pain relief", "painful neuropathy", "peripheral pain", "pressure", "professor", "programs", "social", "subcutaneous", "tactile stimulation", "theories", "trait" ], "approved": true } }, { "type": "Grant", "id": "10519", "attributes": { "award_id": "1R43IP001195-01", "title": "mRNA-BASED VACCINE AGAINST MULTIPLE COVID-19 VARIANTS", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-30", "end_date": "2023-09-29", "award_amount": 252010, "principal_investigator": { "id": 26528, "first_name": "Mohammed", "last_name": "Bouziane", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1937, "ror": "", "name": "SUNOMIX THERAPEUTICS", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Over the last 25 months humanity has been confronting COVID-19 pandemic caused by the new Corona Virus 2 (SARS-CoV-2) infection. Mutations and deletions often occur in the genome of SARS-CoV-2 (predominantly in the Spike protein) resulting in more transmissible and pathogenic “variants of concern” (VOCs). Our long- term goal is to develop a potent COVID-19 vaccine to stop/reduce SARS-CoV-2 infections and/or COVID-19 disease caused by multiple VOCs. Major gaps: Out of the 50 mutations that occur in the genome of OMICRON variant, 32 mutations are concentrated in the Spike protein sequence alone. Because most mutation and deletion that produced the 20 known VOCs are mostly concentrated on the Spike protein sequence, there is a risk that some of current COVID-19 sub-unit vaccines, that used mainly the Spike protein as antigen, fail to protect against future VOCs despite inducing strong virus-specific neutralizing antibodies. This emphasizes two major gaps in knowledge: The need to design alternative second-generation coronaviruses vaccines that (1) will include non- structural epitopes and antigens (Ags), other than the Spike protein; and (2) will incorporate conserved B and T cell epitopes to induce cell-mediated immune responses (in addition to humoral responses). Preliminary Results: We: (1) Identified potential human T cell target epitopes (the part of a virus antigens that the immune system recognizes) from the whole SARS-CoV-2 genome; and (2) Produced a first prototype multi-epitope COVID-mRNA vaccine candidate using the scalable and proven mRNAs vaccine platform, and (3) Generated a novel “humanized” susceptible HLA-DR/HLA-A*0201/hACE2 triple transgenic mouse model in which to test additional COVID-mRNA-based vaccine candidates. We hypothesize that one of our 5 COVID-19 vaccine candidates will protect “humanized” mice from infection and COVID-like disease caused by intranasal inoculation with SARS-CoV-2 a, b, g, d and Omicron VOCs. Our Specific Aims are: Aim 1: To construct 5 additional multi- epitopes COVID-mRNA-based vaccine candidates, that will incorporate conserved B and T cell epitopes from SARS-CoV-2 VOCs that circulate in the United Sates and other 200 other countries. Aim 2: To test in our novel “humanized” mouse model the safety, immunogenicity, and protective efficacy against SARS-CoV-2 a, b, g, d or Omicron VOCs of 5 multi-epitope COVID-mRNA vaccine candidates, delivered intranasally. The durability of protection and its correlation with blocking/neutralizing antibodies and the number and function of tissue-resident SARS-CoV-2-specific CD4+ and CD8+ TRM cells in the lungs and brains will be determined. If successful, the lead vaccine that protects against most VOCs, will be tested in non-human primate for safety (SBIR Phase II) and subsequently could be moved quickly into an FDA Phase 1 clinical trial.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10479", "attributes": { "award_id": "272201600013C-P00026-9999-16", "title": "MICROBIOLOGY AND INFECTIOUS DISEASES BIOLOGICAL RESEARCH REPOSITORY (MID BRR) - SARS-CoV-2 THERAPEUTICS RESEARCH RELATED ACTIVITIES", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-05-05", "end_date": "2023-05-04", "award_amount": 2924707, "principal_investigator": { "id": 24837, "first_name": "TIMOTHY", "last_name": "STEDMAN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1788, "ror": "https://ror.org/03thhhv76", "name": "American Type Culture Collection", "address": "", "city": "", "state": "VA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1788, "ror": "https://ror.org/03thhhv76", "name": "American Type Culture Collection", "address": "", "city": "", "state": "VA", "zip": "", "country": "United States", "approved": true }, "abstract": "This contract provides unique and quality-assured infectious reagents and resources to the scientific community for use in basic research and product development. The scope of this contract includes the acquisition, authentication, production, preservation, storage, and distribution of research and reference reagents to the research community. These reagents span the pathogens in the Division of Microbiology and Infectious Diseases portfolio, and include the National Institutes of Allergy and Infectious Disease (NIAID) Category A, B and C Priority Pathogens and emerging infectious diseases.", "keywords": [ "2019-nCoV", "Basic Science", "COVID-19", "COVID-19 therapeutics", "Categories", "Communicable Diseases", "Communities", "Contracts", "Emerging Communicable Diseases", "Microbiology", "National Institute of Allergy and Infectious Disease", "Production", "Reagent", "Research", "Resources", "Therapeutic Human Experimentation", "biological research", "pathogen", "preservation", "priority pathogen", "product development", "repository", "research and development" ], "approved": true } }, { "type": "Grant", "id": "10503", "attributes": { "award_id": "3U24HG007008-09S1", "title": "Institute of Human Virology H3Africa Biorepository (I-HAB) ADMIN SUPPLEMENT", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Human Genome Research Institute (NHGRI)" ], "program_reference_codes": [], "program_officials": [ { "id": 26498, "first_name": "Jennifer L", "last_name": "Troyer", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-16", "end_date": "2023-06-30", "award_amount": 345798, "principal_investigator": { "id": 22793, "first_name": "Alash'le G.", "last_name": "Abimiku", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [ { "id": 1539, "ror": "https://ror.org/02e66xy22", "name": "Institute of Human Virology", "address": "", "city": "", "state": "", "zip": "", "country": "NIGERIA", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1539, "ror": "https://ror.org/02e66xy22", "name": "Institute of Human Virology", "address": "", "city": "", "state": "", "zip": "", "country": "NIGERIA", "approved": true }, "abstract": "The Institute of Human Virology Nigeria (IHVN) H3Africa biorepository (I-HAB), has successfully upgraded its practices to be ISBER compliant through an iterative quality assessment-based interaction involving capacity building drawing upon Coriell’s proven models and graduated to be the W/Africa H3Africa regional biorepository, During the COVID-19 pandemic, I-HAB lost 18 months of its planned activities due to the disruption of services by the pandemic. So far, I-HAB has only successfully received and aliquoted all DNA biospecimens from only one of the six H3Africa research projects that it supports. Two of the projects deposited 67% and 86% while the rest of the three projects are below 50% submission; at only 0%, 17%, and 29%. The goal of this administrative supplemental submission (1 JULY 2022 TO 30 JUNE 2023) is to ensure that all remaining biospecimens are deposited by H3Africa investigators, aliquoted, and used in the final phase which is to distribute aliquoted biospecimens and data to investigators from the wider scientific community whose application has been approved by the Data and Biospecimen Advisory Committee (DBAC) to conduct high-quality genomics and translational research in Africa using well processed, preserved and quality controlled and redundantly protected human biological samples. To achieve this, I-HAB builds on its past successes to address four specific aims. 1) Engage PIs to complete deposition and create sub-aliquots of primary human biologic samples and genetic materials in compliance with GLP, ISBER guidelines, and QC 10% in line with H3Africa policies/ guidelines. 2) Populate, interrogate, and query the database regularly to ensure that the online catalogue is up to date, interfacing regularly with other two regional H3Africa biorepositories, the H3AfricaBionet team, and relevant stakeholders to review and brainstorm on ways to address gaps during scheduled meetings. 3) Pilot processes for efficient distribution of high- quality biological samples to the wider scientific community, based on Data and Biological samples Access Committee approval and according to H3Africa policies and guidelines. 4) Strengthen I-HAB’s business model as part of a long-term sustainability strategy. Working collaboratively with the other two sister H3Africa biorepositories and the H3Africa Bionet, I-HAB continues to advocate for host government and community support and pilot processes to make the regulatory and ethical process of sharing samples and data easier. The strong institutional support through the expansion of the biorepository to over 3times its size at IHVN’s new facility, the acquirement of a liquid nitrogen plant, and the expansion of its clientele to investigators outside of H3Africa signals a sustainable future for I- HAB.", "keywords": [ "Address", "Administrative Supplement", "Advisory Committees", "Advocate", "Africa", "African", "Aliquot", "Bioinformatics", "Biological", "Businesses", "COVID-19 pandemic", "Catalogs", "Clinical Data", "Communities", "DNA", "Data", "Deposition", "Disease", "Ensure", "Ethics", "Future", "Genes", "Genetic Materials", "Genomics", "Goals", "Government", "Grant", "Guidelines", "Health", "Human", "Human Resources", "Infrastructure", "Institutes", "Leadership", "Liquid substance", "Mentors", "Modeling", "Nigeria", "Nitrogen", "Persons", "Phase", "Plants", "Policies", "Population", "Process", "Public Health", "Race", "Research", "Research Personnel", "Research Project Grants", "Resources", "Rest", "Sampling", "Schedule", "Science", "Scientist", "Services", "Shipping", "Signal Transduction", "Sister", "Time", "Training", "Translational Research", "Work", "base", "biobank", "clinical research site", "database query", "epidemiologic data", "global health", "high standard", "improved", "meetings", "pandemic disease", "preservation", "sample collection", "success", "virology" ], "approved": true } }, { "type": "Grant", "id": "10495", "attributes": { "award_id": "75N93022C00047-0-9999-1", "title": "REAL-TIME SURVEILLANCE OF VACCINE MISINFORMATION FROM SOCIAL MEDIA PLATFORMS", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-08-08", "end_date": "2023-08-07", "award_amount": 300000, "principal_investigator": { "id": 26502, "first_name": "JINGCHENG", "last_name": "DU", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1763, "ror": "", "name": "MELAX TECHNOLOGIES, INC.", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "To develop digital tools to identify and combat malicious digital bots that spread misinformation about infectious disease treatments and vaccines, including COVID-19 vaccines.", "keywords": [ "Basic Science", "COVID-19 vaccine", "Coronavirus", "Misinformation", "Severe Acute Respiratory Syndrome", "Time", "Vaccines", "combat", "digital", "infectious disease treatment", "social media", "tool" ], "approved": true } }, { "type": "Grant", "id": "10471", "attributes": { "award_id": "3F31CA224806-04S1", "title": "Redox modulation - Impact on Tumor Growth and Therapeutic Anticancer Efficacy", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [ { "id": 24807, "first_name": "ANTHONY THOMAS", "last_name": "Dibello", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-03-01", "end_date": "2023-02-28", "award_amount": 26352, "principal_investigator": { "id": 26482, "first_name": "Michael Yi", "last_name": "Bonner", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1936, "ror": "https://ror.org/056d84691", "name": "Karolinska Institute", "address": "", "city": "", "state": "", "zip": "", "country": "SWEDEN", "approved": true }, "abstract": "Despite advances in cancer biology, drug resistance is a major obstacle to patients and clinicians. Many cancer therapeutics elevate reactive oxygen species (ROS) production, often leading to regression followed by reoccurrence and therapeutic resistance. This project continues work published by Kelkka et al. which observed tumor growth inhibition in mice carrying a loss of function mutation in the Ncf1 molecule of the Nox2 complex (Kelkka, T. et al. 2013). Given that Ncf1 mutant mice are more susceptible to animal models of human autoimmune diseases (Zhong, J. et al. 2018), immune cells may be more efficacious against metastasis and tumor progression when ROS production in leukocytes is inhibited. However, their studies did not identify which leukocyte plays the major role in the Nox2-mediated tumor growth, presenting possible targets for cancer therapy. Currently five clinical trials are evaluating Auranofin, an FDA approved thioredoxin reductase 1 (TrxR) inhibitor, as a possible treatment for malignancies such as glioblastoma, ovarian cancer, lung carcinoma, and leukemia. Earlier studies have shown that inhibition of TrxR in tumors suppresses, in vivo tumor progression (Stafford, W. C. et al. 2018, Yoo, M. H. et al. 2006). However, these studies, and a vast majority of studies to-date, have limited testing of Auranofin to immuno-compromised animal models. We have strong evidence that TrxR inhibition in immune-competent animals significantly promote tumor growth of solid murine syngeneic tumors such as the B16F10 melanoma and the Lewis Lung Carcinoma (LLC) models. Our studies are supported by overlooked, yet convincing studies in the literature (Hiramoto, K. et al. 2014, Mirabelli, C. K. et al. 1985). Therefore, we also aim to show that inhibition of TrxR in dendritic cells or B cells may promote tumor progression. This reorganized PhD project, having been heavily affected by COVID due to dependence on multiple breeding, will finalize experiments for two high-impact manuscripts for publication aimed at journals such as Cell or Immunity: 1) A manuscript establishing the therapeutic potential of targeting Ncf1-Nox2 in syngeneic dendritic cells for use against B16F10 and LLC cancer models; 2) a manuscript establishing the effects of TrxR1 inhibition in dendritic cells and mechanism for promoting B16F10 and LLC tumor growth, and its implication for anticancer therapy. We will use six mouse strains to help us understand the significance of host Redox biology in cancer immune surveillance. Specifically, we will use mouse models with key phenotypes: BQ.Txnrd1Flox, BQ.Ncf1m1J (Ncf1 mutant mice), BQ.CD11c-cre, BQ.MB1-cre, BQ.CD4-cre, and BQ.TN3 conditional Ncf1 wildtype knock- in mice. If successful, this will be of therapeutic significance.", "keywords": [ "Adoptive Transfer", "Affect", "Animal Model", "Animals", "Antigens", "Antioxidants", "Auranofin", "Autoimmune Diseases", "B-Lymphocytes", "Biology", "Breeding", "Cancer Biology", "Cancer Model", "Cancer Patient", "Cells", "Clinical", "Clinical Trials", "Complex", "Cysteine", "Dendritic Cells", "Dependence", "Development", "Doctor of Philosophy", "Drug resistance", "FDA approved", "Genetic", "Glioblastoma", "Growth", "ITGAX gene", "Immune", "Immunity", "Immunocompetent", "Immunocompromised Host", "Immunologic Surveillance", "Journals", "Knock-in Mouse", "Knock-out", "Knowledge", "Leukocytes", "Lewis Lung Carcinoma", "Lewis lung carcinoma cell", "Literature", "Malignant - descriptor", "Malignant Neoplasms", "Malignant neoplasm of ovary", "Manuscripts", "Mediating", "Modeling", "Mouse Strains", "Mus", "Mutant Strains Mice", "Mutation", "Neoplasm Metastasis", "Nuclear", "Organism", "Oxidation-Reduction", "Patients", "Pharmacology", "Phenotype", "Play", "Production", "Proteome", "Proteomics", "Publications", "Publishing", "Reactive Oxygen Species", "Research Project Grants", "Role", "Solid", "System", "Testing", "Therapeutic", "Work", "anti-cancer therapeutic", "cancer therapy", "cell transformation", "coronavirus disease", "experimental study", "human model", "improved", "in vivo", "inhibitor", "insight", "leukemia", "loss of function mutation", "lung Carcinoma", "melanoma", "mouse model", "mutant", "premalignant", "public health relevance", "targeted cancer therapy", "therapy resistant", "thioredoxin reductase 1", "transcription factor", "tumor", "tumor growth", "tumor progression" ], "approved": true } }, { "type": "Grant", "id": "10511", "attributes": { "award_id": "1U01CK000671-01", "title": "Midwest Virtual Laboratory of Pathogen Transmission in Healthcare Settings (MVL-PATHS)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-30", "end_date": "2025-09-29", "award_amount": 299761, "principal_investigator": { "id": 26517, "first_name": "Majid", "last_name": "Bani Yaghoub", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 753, "ror": "", "name": "UNIVERSITY OF MISSOURI KANSAS CITY", "address": "", "city": "", "state": "MO", "zip": "", "country": "United States", "approved": true }, "abstract": "Midwest Virtual Laboratory of Pathogen Transmission in Healthcare Settings (MVL-PATHS) Project Summary Antimicrobial Resistant (AMR) pathogens have become a significant public health threat. Also, the COVID-19 pandemic has further revealed disparities in healthcare settings. By developing and implementing novel mathematical and computation models, the long-term goals are to optimize AMR control and preventive interventions and to improve the health equity. The central hypothesis is that the outputs of mathematical and computation models will provide optimized and effective guidelines to reduce the threat of AMR pathogen spread and reduce health disparities in healthcare settings. The rationale underlying this project is to fill the critical gap in modeling workforce capacity and develop a new generation of mathematical models for healthcare research. The central hypothesis will be tested by pursuing three specific aims to develop and employ a, (i) One Health modeling approach to understand the source, distribution and spread of AMR Enterobacteriaceae with a focus on Extended- spectrum beta-lactamase (ESBL)-producing E. coli, (ii) a novel Real-Time modeling approach to identify AMR pathogen transmission by asymptomatic spreaders and contaminated medical devices in hospitals, (iii) a novel Agent-Based Nested modeling approach to identify the effects of caregivers as vectors of disease spread, and effects of limited staffing and specialized care on equitable quality of care in nursing homes. We will pursue these aims using an innovative combination of mathematical and computational modeling techniques. These include both recently developed techniques of including human behavior in models and more-established techniques that have been applied very little to the study of health equity and AMR pathogen spread. The workforce development objectives of this proposal are to (i) enhance mathematical and computational modeling research capabilities of the public health workforce and (ii) increase the number of junior modeling professionals that are trained and experienced in modeling transmission of pathogens in healthcare settings partly incorporated with health disparities. The expected outcomes of this work are the successful training of five predoctoral fellows and creating a virtual laboratory of enhanced mathematical models to identify strategies for reducing the threat AMR pathogen spread and reducing health disparities. The results will have an important positive impact immediately because the virtual laboratory can also be used by healthcare professionals to further investigate the drivers of disease spread and estimate the relative benefits of multiple control and prevention strategies in a timely and cost-effective manner. In addition, the research outputs of this project will expand and strengthen national one-health efforts to combat resistance and will have a direct impact on CDC and its public health partners’ ability to reduce the costs, morbidity and mortality of healthcare associated infections.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10431", "attributes": { "award_id": "1R01AA029819-01", "title": "Impact of high deductible health plans and COVID-19 on alcohol use disorder treatment access, outcomes, and disparities", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Alcohol Abuse and Alcoholism (NIAAA)" ], "program_reference_codes": [], "program_officials": [ { "id": 6777, "first_name": "LAURA ELIZABETH", "last_name": "Kwako", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-20", "end_date": "2026-08-31", "award_amount": 738786, "principal_investigator": { "id": 26429, "first_name": "James Franklin", "last_name": "Wharam", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 246, "ror": "https://ror.org/00py81415", "name": "Duke University", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "Excessive alcohol use is the 5th-leading risk factor for premature death and disability. The health and economic burden associated with alcohol use is concentrated in ~14 million adults with alcohol use disorder. Pharmacological and behavioral interventions, especially when combined, reduce alcohol use and related harms and assist long-term recovery. However, only ~5% adults with alcohol use disorder receive formal treatment in health care settings. Recent societal phenomena, namely the rapid rise of high-deductible health plans and the 2019 novel coronavirus pandemic (COVID-19), might contribute to delayed alcohol use disorder diagnosis and treatment. Deferred care might especially affect disadvantaged populations such as low-income and rural residents. In the last decade, high-deductible plans requiring potentially prohibitive out-of-pocket payments for alcohol use disorder services have expanded rapidly, now covering 57% of workers. The COVID- 19 pandemic led to stay-at-home orders and closure of nonessential businesses, dramatically reducing healthcare use. The overarching goal of this proposal is to examine major societal factors affecting alcohol use disorder treatment access and disparities, including modifiable high-deductible health plans and the COVID-19 pandemic. The study will assess alcohol use disorder-related measures before and after 2 key change dates of interest: the date that employers mandate a switch to high-deductible health plans (using a rolling cohort accrual period), and March 2020 when COVID-19 pandemic-related restrictions began. More specifically, the project seeks to: (1) determine the effect of high-deductible health plans on alcohol use disorder diagnosis, treatment, and adverse outcomes; (2) assess whether high-deductible health plans increase disparities in alcohol use disorder diagnosis, treatment, and adverse outcomes; and (3) examine the 4-year impact of the COVID-19 pandemic on disparities in alcohol use disorder diagnosis, treatment, and adverse outcomes The study will draw from an 18-year rolling sample (2007-2024) of ~50 million members aged 18-64 enrolled through a national health insurer. The study will apply rigorous, quasi-experimental interrupted time series designs with segmented regression and segmented survival analyses. We expect that findings will demonstrate the health insurance benefit designs that optimize access to AUD treatment, informing potential modifications to Internal Revenue Service regulations that exempt certain services from high out-of-pocket costs under high-deductible plans. Findings could also help inform post-pandemic policymaking by identifying subgroups at risk of delayed diagnosis and treatment.", "keywords": [ "2019-nCoV", "Acceleration", "Accident and Emergency department", "Adoption", "Adult", "Adverse event", "Affect", "Affordable Care Act", "Alcohol consumption", "Alcoholic Intoxication", "Alcohols", "American", "Behavior Therapy", "Bipolar Disorder", "Businesses", "COVID-19", "COVID-19 pandemic", "COVID-19 pandemic effects", "Caring", "Cessation of life", "Cohort Studies", "Data", "Deductibles", "Diabetes Mellitus", "Diagnosis", "Economic Burden", "Economics", "Emergency Situation", "Enrollment", "Ethnic Origin", "Family", "Financial Hardship", "Funding", "Goals", "Health", "Health Insurance", "Health Services Accessibility", "Healthcare", "Home", "Insurance", "Insurance Benefits", "Insurance Carriers", "Interruption", "Low income", "Measures", "Modification", "Outcome", "Outcome Study", "Persons", "Pharmaceutical Preparations", "Pharmacological Treatment", "Pharmacology", "Population", "Poverty", "Privatization", "Race", "Readiness", "Recovery", "Regulation", "Reporting", "Research Design", "Resources", "Risk", "Risk Factors", "Sampling", "Series", "Services", "Societal Factors", "Statutes and Laws", "Subgroup", "Substance Use Disorder", "Survival Analysis", "Time", "Treatment Cost", "Treatment outcome", "United States", "adverse outcome", "aged", "alcohol availability", "alcohol risk", "alcohol use disorder", "barrier to care", "behavioral health", "cohort", "comparison group", "cost", "data infrastructure", "design", "diagnostic criteria", "disability", "disadvantaged population", "ethnic minority population", "experience", "health care settings", "health economics", "health plan", "health savings account", "high risk", "improved", "interest", "malignant breast neoplasm", "member", "pandemic coronavirus", "pandemic disease", "parity", "payment", "premature", "racial and ethnic", "reduced alcohol use", "rehabilitation service", "rural dwellers", "rurality", "social", "treatment disparity", "trend" ], "approved": true } } ], "meta": { "pagination": { "page": 1, "pages": 1424, "count": 14236 } } }